U.S. Bill Aims To Streamline Combo Product Regulation
This article was originally published in PharmAsia News
In a move that could affect applicants from Asia and elsewhere, a U.S. Senate bill aims to streamline device/drug combination registrations at the FDA by letting the agency rely on prior premarket approvals and approved drug findings to help support new product approvals, among other reforms.
You may also be interested in...
More external infusion pumps used in the home and continuous glucose monitors for diabetics would be reimbursed under a proposed Medicare agency rule.
Device Week, 30 October 2020 – Medtech Money Influences US Elections; User-Fee Negotiations Kick Off
In this week’s podcast we discuss which political candidates are getting campaign donations from the medtech industry in the 2020 US Senate and House elections, and where the FDA and other stakeholders – including the medtech industry – stand as device user-fee negotiations get underway.
A final Medicare agency rule requiring insurers to reveal coverage prices for device-related procedures and tests will let consumers shop health services.